STRATEGY TO MINIMIZE THE BLEEDING RISKS IN PATIENTS WITH ATRIAL FIBRILLATION WHO RECEIVE COMBINED ANTITHROMBOTIC THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION
The use of combined antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary interventions is associated with an increased risk of bleeding. In this regard, minimizing haemorrhagic risk is one of the strategic priorities in the management of this clinical group...
Main Author: | D. A. Zateishchikov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«REMEDIUM GROUP» Ltd.
2018-05-01
|
Series: | Атеротромбоз |
Subjects: | |
Online Access: | https://www.aterotromboz.ru/jour/article/view/148 |
Similar Items
-
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
by: James S Kalus
Published: (2013-04-01) -
ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES
by: Ya. P. Dovgalevskiy, et al.
Published: (2016-01-01) -
Modern strategy of antithrombotic therapy in patients with coronary artery disease and atrial fibrillation after percutaneous coronary intervention
by: Yu. A. Karpov
Published: (2019-12-01) -
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
by: Hyeongsoo Kim, et al.
Published: (2020-01-01) -
Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows
by: Luca Masotti, et al.
Published: (2012-10-01)